Business Description
Imunon Inc
NAICS : 325412
SIC : 2834
Description
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.87 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | -0.28 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -8.54 | |||||
| Beneish M-Score | -3.07 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -40.1 | |||||
| 3-Year EBITDA Growth Rate | 40.3 | |||||
| 3-Year EPS without NRI Growth Rate | 27.8 | |||||
| 3-Year FCF Growth Rate | 20.8 | |||||
| 3-Year Book Growth Rate | -16.5 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54 | |||||
| 9-Day RSI | 43.83 | |||||
| 14-Day RSI | 41.66 | |||||
| 6-1 Month Momentum % | -16.47 | |||||
| 12-1 Month Momentum % | -72.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.75 | |||||
| Quick Ratio | 4.75 | |||||
| Cash Ratio | 4.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -66.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -4697.2 | |||||
| Net Margin % | -5377.2 | |||||
| ROE % | -53.82 | |||||
| ROA % | -39.11 | |||||
| ROIC % | -105.9 | |||||
| ROC (Joel Greenblatt) % | -2161.04 | |||||
| ROCE % | -37.76 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 16.63 | |||||
| PB Ratio | 0.23 | |||||
| Price-to-Tangible-Book | 0.34 | |||||
| EV-to-EBIT | 0.9 | |||||
| EV-to-EBITDA | 0.93 | |||||
| EV-to-Revenue | -41.91 | |||||
| EV-to-FCF | 0.9 | |||||
| Price-to-Net-Current-Asset-Value | 0.45 | |||||
| Price-to-Net-Cash | 0.52 | |||||
| Earnings Yield (Greenblatt) % | 111.11 |
How Imunon Inc (IMNN) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMNN
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Imunon Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.5 | ||
| EPS (TTM) ($) | -4.272 | ||
| Beta | 1.95 | ||
| Volatility % | 59.5 | ||
| 14-Day RSI | 41.66 | ||
| 14-Day ATR ($) | 0.088223 | ||
| 20-Day SMA ($) | 1.3795 | ||
| 12-1 Month Momentum % | -72.8 | ||
| 52-Week Range ($) | 1.26 - 7.68 | ||
| Shares Outstanding (Mil) | 7.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Imunon Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Imunon Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Imunon Inc Frequently Asked Questions
What is Imunon Inc(IMNN)'s stock price today?
The current price of IMNN is $1.33. The 52 week high of IMNN is $7.68 and 52 week low is $1.26.
When is next earnings date of Imunon Inc(IMNN)?
The next earnings date of Imunon Inc(IMNN) is 2023-05-13 Est..
Does Imunon Inc(IMNN) pay dividends? If so, how much?
Imunon Inc(IMNN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
